Results 191 to 200 of about 429,043 (216)

Treatment of axial spondyloarthritis: an update

Nature Reviews Rheumatology, 2022
Diagnosis and management of axial spondyloarthritis (axSpA) has vastly improved over the past two decades. With advances in the discernment of immunopathogenesis of this disease, new therapies have become available, which are associated with substantial improvement in symptoms, signs and quality of life.
Abhijeet Danve, Atul Deodhar
openaire   +2 more sources

Anti-TNFs in axial spondyloarthritis

Wiener Medizinische Wochenschrift, 2015
Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity.
Roland, Kocijan, Christian, Muschitz, Jürgen, Rech   +2 more
openaire   +2 more sources

Axiale Spondyloarthritis

Schmerzmedizin, 2022
D. Kiefer, J. Braun, U. Kiltz
openaire   +2 more sources

The Future of Imaging in Axial Spondyloarthritis

Rheumatic Disease Clinics of North America, 2020
This article discusses the current position of conventional radiography and MRI, the techniques recommended by the European League Against Rheumatism for use in imaging in axial spondyloarthritis (axSpA). Several challenges and areas of development regarding radiography and MRI in axSpA are considered.
openaire   +2 more sources

Golimumab for the treatment of axial spondyloarthritis

Expert Opinion on Biological Therapy, 2016
Anti-TNF drugs have represented an epochal revolution in the treatment of rheumatoid arthritis and spondyloarthritis. In the field of axial spondyloarthritis, golimumab, a fully human monoclonal anti-TNFα administered subcutaneously every 4 weeks, has shown significant efficacy and good safety in patients with ankylosing spondylitis.
Carlo, Palazzi, Salvatore, D'angelo, Michele, Gilio, Pietro, Leccese, Angela, Padula, Ignazio, Olivieri   +5 more
openaire   +2 more sources

Upadacitinib for the Treatment of Active Non-Radiographic Axial Spondyloarthritis (SELECT-AXIS 2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Lancet, The, 2022
Peter Wung, In-Ho Song, Aileen L Pangan
exaly  

Upadacitinib for the Treatment of Active Non-Radiographic Axial Spondyloarthritis

Lancet, The, 2022
Maureen Dubreuil, Jean Liew
exaly  

Axiale Spondyloarthritis

MSK – Muskuloskelettale Physiotherapie, 2021
openaire   +2 more sources

Ixekizumab for Patients With Non-Radiographic Axial Spondyloarthritis (COAST-X): A Randomised, Placebo-Controlled Trial

Lancet, The, 2020
Alan Kivitz, Walter P Maksymowych, Atul Deodhar   +2 more
exaly  

Inhibition of Interleukin-17 in Axial Spondyloarthritis Spectrum

Lancet, The, 2020
Pedro M Machado
exaly